Pharmaceuticals, Biotechnology and Life Sciences
The advanced compounding bases cover a broad range of therapeutic categories. NEW BRUNSWICK, N.J.–(BUSINESS WIRE)–#SpectrumRxProds—Spectrum Pharmacy Products, a division of…
NEW YORK–(BUSINESS WIRE)–Aptorum Group Limited (“Aptorum Group” or the “Company”) (NASDAQ: APM), a biopharmaceutical company focused on the development of…
NEW YORK–(BUSINESS WIRE)–Aptorum Group Limited (Nasdaq: APM) (“Aptorum Group”), a biopharmaceutical company focused on the development of novel therapeutics to…
Eli Lilly’s test of oral selpercatinib monotherapy for the treatment of RET fusion-positive non-small cell lung cancer (NSCLC) saw a 68 percent objective response rate (ORR), and also showed that safety analysis of all 531 patients enrolled to LIBRETTO-001, selpercatinib was well-tolerated, with only 9 patients (1.7%) discontinuing therapy due to treatment-related toxicity.
Standard & Poor’s (S&P) assigned a BBB- credit rating with stable outlook to Vifor Pharma.
– 44% of patients achieved a response and nearly half (48%) maintained disease control at week 12 (efficacy as secondary…
BOSTON–(BUSINESS WIRE)–PureTech Health plc (LSE: PRTC), today announced that Joichi “Joi” Ito, Ph.D., has stepped down from the board of…
The U.S. Food and Drug Administration granted Breakthrough Therapy Designation to capmatinib (INC280) as a first-line treatment for patients with metastatic MET exon14 skipping-mutated non-small cell lung cancer (NSCLC), said John Tsai, MD, Head of Global Drug Development and Chief Medical Officer, Novartis.
Selvita has dosed the first patient in its Phase 1b study of CDK8 inhibitor, SEL120, which is being initially investigated in the treatment of patients with acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (HR-MDS).
PARIS–(BUSINESS WIRE)–Step Pharma, a biotech company developing novel drugs for autoimmune diseases, today announced the appointment of Andrew Parker, Ph.D.,…